The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib
Huaqi Wang,Zhiwei Wang,Zhenyu Hou,Xuejiao Yang,Keyun Zhu,Manqing Cao,Xiaolin Zhu,Huikai Li,Ti Zhang
DOI: https://doi.org/10.2147/CMAR.S311526
2021-09-07
Cancer Management and Research
Abstract:Huaqi Wang, 1, &ast Zhiwei Wang, 1, &ast Zhenyu Hou, 1 Xuejiao Yang, 1 Keyun Zhu, 1 Manqing Cao, 2 Xiaolin Zhu, 1 Huikai Li, 1 Ti Zhang 1, 3 1 Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital; Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China; 2 Department of Breast Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China; 3 Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ti Zhang Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, People's Republic of China Tel/Fax +86-21-6417-5590 Email Huikai Li Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, 24 Bin Shui Road, Hexi District, Tianjin, 300060, People's Republic of China Tel/Fax +86-22-2335-9984 Email Purpose: Patients with hepatocellular carcinoma (HCC) who might benefit most from anti-angiogenesis therapy remain unknown. In recent years, neutrophil-to-lymphocyte ratio (NLR), an indicator of inflammatory response, has received particular attention in HCC. Herein, we explored the prognostic value of pre-treatment NLR in individuals with unresectable intermediate and advanced hepatocellular carcinoma treated with apatinib, a second-line angiogenesis inhibitor. The findings of this study would assist in precision medicine and provide clinical decision support. Patients and Methods: This is a retrospective study in which 171 HCC patients attending Tianjin Medical University Cancer Institute and Hospital and treated with apatinib between January 2016 and July 2018 were enrolled. The prognosis of the patients based on NLR signatures was then analyzed. Results: Patients with a low pre-treatment NLR (NLR < 2.49) presented a significantly longer overall survival (OS) (P < 0.001) and progression-free survival (PFS) (P = 0.043). Furthermore, a low pre-treatment NLR level could be used to predict a longer OS in patients with non-macrovascular invasion (P < 0.001). Independent of serum alpha-fetoprotein (AFP) levels, a low NLR level in this cohort of patients is associated with a longer OS. Conclusion: Pre-treatment NLR predicts the prognosis of patients with unresectable intermediate and advanced HCC treated with apatinib. Keywords: hepatocellular carcinoma, vascular endothelial growth factor receptor - 2, neutrophil to lymphocyte ratio, tyrosine protein kinases inhibitor Hepatocellular carcinoma (HCC) is the sixth most prevalent malignant tumor and the third leading cause of cancer-related deaths. 1 Approximately 40% of HCC patients are diagnosed at advanced stages and the majority of them have limited access to radical treatments. 2 Sorafenib and lenvatinib, two tyrosine protein kinase inhibitors (TKI), are the major targeted therapies against HCC. 3–5 Indeed, compared to placebo, sorafenib was demonstrated to be effective by prolonging the median OS by 3 months, and lenvatinib presented a non-inferiority OS to that of sorafenib. 5,6 Apatinib is a novel highly selective small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-2, with a strong antitumor activity against numerous cancers, including gastric cancer, breast cancer, ovarian cancer and liver cancer. 7–11 A Phase III clinical trial has demonstrated that compared to placebo, apatinib markedly improves the objective response rate (ORR) and is thus recommended as a second-line treatment for advanced HCC. 12 Apatinib also substantially prolongs the OS of patients with sorafenib-refractory advanced HCC. 13 In addition, apatinib may also present its vital and outstanding characteristics in optimization and regulation in tumor immune microenvironment, which exerts synergistic anti-cancer effects in combination with immunotherapy. 14,15 However, the lack of the predictive biomarkers for anti-angiogenesis th -Abstract Truncated-
oncology